Dulaglutide (Trulicity) in 2026: Newest Evidence on Weight, Heart Protection, and How It Compares to Semaglutide and Tirzepatide

TL;DR: Dulaglutide is a once-weekly GLP-1 injection for type 2 diabetes with proven heart and kidney benefits. New 2026 data show it remains noninferior to tirzepatide for cardiovascular outcomes, but semaglutide and tirzepatide produce greater weight loss in most comparisons.
Important clarification: “Dulcoglide” is often used online as a misspelling or confusion with dulaglutide, the active ingredient in Trulicity. DulcoGlide itself is a separate product — a rectal applicator for suppositories — and has no role in diabetes or weight management. This article covers dulaglutide, the GLP-1 medication.
Introduction
If you searched for “Dulcoglide” expecting a GLP-1 drug, you’ve landed in the right place — but the name needs correcting. The medication is dulaglutide, sold as Trulicity. It’s been on the market since 2014, yet 2026 has produced some of the most important head-to-head data in its history.
This guide gives you the newest evidence, not recycled 2023 talking points. You’ll see how dulaglutide performed against tirzepatide in the SURPASS-CVOT trial, what the 2026 ADA guidelines say about its place in therapy, and why real-world weight-loss numbers tell a more honest story than marketing claims.
Quick Overview: Dulaglutide in 2026
- Drug class: Once-weekly GLP-1 receptor agonist injection.
- Approved uses: Type 2 diabetes (adults and children 10+); reducing major cardiovascular events in adults with established CVD or multiple risk factors .
- 2026 ADA positioning: Recommended alongside semaglutide and liraglutide for patients with established cardiovascular disease, based on proven benefit .
- Dosing: Starts at 0.75 mg weekly; titrates to 1.5 mg, 3 mg, or 4.5 mg with medical guidance .
- Weight-loss efficacy (ADA 2026): Classified as “high” at high doses — below semaglutide and tirzepatide, but still clinically meaningful .
- Key 2026 trial: SURPASS-CVOT showed tirzepatide was noninferior — not superior — to dulaglutide for cardiovascular outcomes .
What Is Dulaglutide and How Does It Work?
Definition: Dulaglutide is a long-acting GLP-1 receptor agonist. It mimics a gut hormone released after eating, improving insulin release, slowing digestion, and reducing appetite.
Dulaglutide binds to GLP-1 receptors in the pancreas, brain, and gut. The result is glucose-dependent insulin secretion, suppressed glucagon, slower gastric emptying, and reduced calorie intake. Because it’s attached to an Fc fragment, it survives longer in the body and is injected just once weekly .
How It Works: A Step-by-Step Breakdown
- Once-weekly injection into the abdomen, thigh, or upper arm.
- GLP-1 receptor activation triggers insulin release only when glucose is high, lowering hypoglycaemia risk when used alone.
- Stomach emptying slows, extending fullness after meals.
- Appetite signalling shifts, often reducing food cravings and total calorie intake.
- Cardiovascular and renal protection emerges over months to years, partly through effects on inflammation, blood pressure, and albuminuria .
The Newest Cardiovascular Evidence: SURPASS-CVOT Changes the Conversation
The biggest 2025–2026 story is SURPASS-CVOT, published in NEJM in December 2025 and presented at ACC 2026. It was the first major trial to compare tirzepatide head-to-head against dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease.
The result matters: over a median follow-up of four years, the primary cardiovascular endpoint occurred in 12% of the tirzepatide group and 13% of the dulaglutide group (HR 0.92; p=0.003 for noninferiority). Tirzepatide was noninferior — it did not clearly beat dulaglutide on hard cardiovascular outcomes .
That’s a meaningful finding. It means dulaglutide’s cardiovascular legacy — built on the REWIND trial, which showed a 12% reduction in MACE versus placebo — remains clinically relevant even in the era of dual and triple agonists . According to the American College of Cardiology’s analysis of SURPASS-CVOT, the cardiovascular gap between these agents is narrower than the weight-loss gap .
Kidney Outcomes Add Another Layer
A pre-specified exploratory analysis of SURPASS-CVOT examined major kidney events. Dulaglutide was not inferior to tirzepatide for the composite kidney outcome, and REWIND post-hoc data had already shown dulaglutide reduces new-onset macroalbuminuria and sustained eGFR decline . For patients with diabetic kidney disease, that renal signal is a practical differentiator when choosing therapy.
How Does Dulaglutide Compare to Semaglutide and Tirzepatide in 2026?
Here’s the honest 2026 picture, backed by the newest meta-analyses and real-world studies.
| Outcome | Dulaglutide (Trulicity) | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|---|
| HbA1c reduction | Strong | Stronger | Strongest at high doses |
| Weight loss (real-world, 52 weeks) | −1.14% body weight | −6.51% body weight | Greater than dulaglutide at high doses |
| Cardiovascular outcomes | Proven MACE reduction (REWIND) | Proven | Noninferior to dulaglutide (SURPASS-CVOT) |
| Kidney outcomes | Reduced macroalbuminuria, eGFR decline | Favorable | Noninferior to dulaglutide |
| Tolerability | GI side effects common but often temporary | GI side effects common | More GI events at higher doses |
| Dosing frequency | Once weekly | Once weekly (injectable); daily (oral) | Once weekly |
A 2026 network meta-analysis confirmed that tirzepatide 15 mg produces the largest HbA1c and weight reductions, while dulaglutide 1.5 mg remains effective for glycaemic control with a more favourable tolerability profile at standard doses . A separate 2026 real-world study in a predominantly African American urban population found semaglutide produced roughly six times greater weight loss than dulaglutide at 52 weeks (−6.51% vs −1.14%) .
The Mazdutide Comparison Matters for Global Readers
A 2026 Nature phase III trial compared mazdutide, a dual glucagon/GLP-1 agonist, with dulaglutide in Chinese adults with type 2 diabetes. Mazdutide produced significantly greater HbA1c and weight reductions than dulaglutide 1.5 mg, with a weight difference of −3.78% to −5.76% . This reinforces the pattern: newer multi-agonist drugs outperform dulaglutide on weight, but dulaglutide remains a benchmark for safety and cardiovascular outcome durability.
Dosing, Safety, and the 2026 FDA Label Updates
The FDA prescribing information was updated in March 2026 with a new warning and precaution for severe gastrointestinal adverse reactions . The boxed warning for thyroid C-cell tumours remains, and dulaglutide is still contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 .
Adult Dosing (2026 Label)
- Start: 0.75 mg subcutaneously once weekly.
- After 4 weeks: May increase to 1.5 mg weekly.
- Further increases: 1.5 mg increments after at least 4 weeks at each dose.
- Maximum: 4.5 mg once weekly .
- Renal impairment: No dose adjustment required, including ESRD .
Paediatric Dosing
Dulaglutide is approved for children 10 years and older with type 2 diabetes. The starting dose is 0.75 mg weekly, with a maximum of 1.5 mg weekly in paediatric patients . A new trial, AWARD-PEDS PLUS, is currently evaluating 3.0 mg and 4.5 mg doses in paediatric participants .
Who Should Avoid It?
- Personal or family history of medullary thyroid carcinoma or MEN 2.
- Prior pancreatitis (use with caution; monitor closely).
- Pregnancy — not approved; human data are limited.
- People taking insulin or sulfonylureas need hypoglycaemia monitoring.
Real-World Weight Loss and Body Composition: What Patients Actually Experience
Clinical trial weight-loss percentages can feel abstract. Real-world data bring the numbers down to earth.
In the 2026 Henry Ford real-world cohort, dulaglutide produced a mean body-weight reduction of about 1.1% at 52 weeks, compared with 6.5% for semaglutide . That doesn’t mean dulaglutide “doesn’t work” for weight — it means its weight effect is modest and gradual, which is consistent with its primary approval as a glucose-lowering and cardiovascular-protective drug.
Body composition studies add nuance. A 2025 analysis found that three months of dulaglutide reduced body weight, visceral fat, and body fat — without significant loss of bone mineral density, and with an increase in lean-mass percentage . That’s a meaningful point for older adults or anyone worried about muscle loss on GLP-1 therapy.
A 2026 proof-of-concept trial in relapsing–remitting multiple sclerosis also reported that adjunctive dulaglutide 0.75 mg weekly for 12 months significantly reduced weight, BMI, body fat, and visceral fat, and improved glucose tolerance — with no adverse events recorded in the dulaglutide group . These are early signals, not approved uses, but they show the metabolic effects extend beyond glucose control.
Key Takeaways
- “Dulcoglide” is not a GLP-1 drug — the medication is dulaglutide (Trulicity), and clarifying that distinction is the first step to trustworthy information.
- SURPASS-CVOT (2025–2026) showed tirzepatide was noninferior, not superior, to dulaglutide for cardiovascular outcomes, preserving dulaglutide’s clinical relevance .
- Weight loss is modest in real-world use (~1% at 52 weeks) compared with semaglutide (~6.5%), so expectations should match the evidence .
- The 2026 ADA guidelines continue to recommend dulaglutide for patients with established cardiovascular disease based on proven MACE reduction .
- Dosing is once weekly, with a maximum of 4.5 mg in adults and 1.5 mg in children 10+ .
FAQ: Real 2026 Search Questions About Dulaglutide
Is Dulcoglide the same as dulaglutide?
No. DulcoGlide is a rectal suppository applicator. Dulaglutide is the GLP-1 medication (Trulicity). They are unrelated products, and “Dulcoglide” is a common search misspelling.
How much weight can you lose on dulaglutide?
Real-world data show modest loss — roughly 1% of body weight at 52 weeks in one 2026 cohort — though clinical trials and body-composition studies show reductions in fat mass and visceral fat .
Is dulaglutide better than tirzepatide?
It depends on the goal. Tirzepatide produces more weight loss and slightly better HbA1c reduction at high doses, but dulaglutide was noninferior for cardiovascular outcomes in SURPASS-CVOT and has a longer safety record .
Does dulaglutide protect the heart?
Yes. REWIND showed a 12% reduction in major adverse cardiovascular events versus placebo, and the FDA label includes an indication for reducing cardiovascular risk in adults with established CVD or multiple risk factors .
Can you take dulaglutide with insulin?
Yes, but the combination increases hypoglycaemia risk. Your doctor may need to reduce the insulin dose when starting dulaglutide. Close glucose monitoring is essential.
What is the newest dulaglutide research in 2026?
The SURPASS-CVOT cardiovascular and kidney analyses, the AWARD-PEDS PLUS paediatric trial, and proof-of-concept work in multiple sclerosis are the most notable 2026 developments .
Conclusion
Dulaglutide doesn’t win the weight-loss headlines in 2026 — and that’s exactly why the newest evidence is worth understanding. SURPASS-CVOT confirmed that its cardiovascular protection stands up to the most powerful new competitor. The ADA still recommends it for people with heart disease. And real-world data give a more honest picture of what “modest weight loss” actually looks like.
If you’re choosing a GLP-1, the right question isn’t “which one is strongest?” It’s “which one matches my heart risk, my kidney function, my weight goals, and my tolerance for side effects?” Dulaglutide remains a credible answer to that question — not because it’s the newest, but because the evidence keeps holding up.



